MedTrace Logo

Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

NCT00445328 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2009-10-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Dalteparin (Fragmin)

Dalteparin 5000 IU once daily subcutaneously for 6-14 days.

DRUG

Unfractionated heparin

Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00445328 on ClinicalTrials.gov